SOCS proteins in regulation of receptor tyrosine kinase signaling

Cellular and Molecular Life Sciences

Volumn 71, Issue 17, 2014, Pages 3297-3310

  Kazi, Julhash U ^a,b,c   Kabir, Nuzhat N ^c   Flores Morales, Amilcar ^d   Rönnstrand, Lars ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c KN Biomedical Research Institute   (Bangladesh)

^d University of Copenhagen   (Denmark)

Author keywords

CSF1R; FLT3; IGF1R; INSR; KIT; PDGFR; SOCS1; SOCS2; SOCS3; SOCS6

Indexed keywords

CD135 ANTIGEN; COLONY STIMULATING FACTOR RECEPTOR; CYTOKINE INDUCIBLE SH2 CONTAINING PROTEIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 2; SUPPRESSOR OF CYTOKINE SIGNALING 3; SUPPRESSOR OF CYTOKINE SIGNALING 4; SUPPRESSOR OF CYTOKINE SIGNALING 5; SUPPRESSOR OF CYTOKINE SIGNALING 6; SUPPRESSOR OF CYTOKINE SIGNALING 7; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

DOWN REGULATION; ENZYME ACTIVATION; ENZYME REGULATION; GENE EXPRESSION; GENE PRODUCT; HUMAN; NONHUMAN; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW; SIGNAL TRANSDUCTION; SOCS1 GENE; SOCS2 GENE; SOCS3 GENE; SOCS4 GENE; SOCS5 GENE; SOCS6 GENE; SOCS7 GENE; TRANSCRIPTION INITIATION; UBIQUITINATION; UPREGULATION;

AMINO ACID MOTIFS; ANIMALS; ENZYME ACTIVATION; HORMONES; HUMANS; MICE; NEOPLASM PROTEINS; NEOPLASMS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 84906216359     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-014-1619-y     Document Type: Review

References (108)

1. Kazi JU, Kabir NN, Soh JW (2008) Bioinformatic prediction and analysis of eukaryotic protein kinases in the rat genome. Gene 410:147-153. doi:10.1016/j.gene.2007.12.003
2. Kabir NN, Kazi JU (2011) Comparative analysis of human and bovine protein kinases reveals unique relationship and functional diversity. Genet Mol Biol 34:587-591. doi:10.1590/S1415-47572011005000035
3. Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141:1117-1134. doi:10.1016/j.cell.2010.06.011
4. Kazi JU, Vaapil M, Agarwal S, Bracco E, Påhlman S, Rönnstrand L (2013) The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling. Cell Signal 25:1852-1860. doi:10.1016/j.cellsig. 2013.05.016
5. Kazi JU, Rönnstrand L (2013) FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia. Mol Oncol 7:402-418. doi:10.1016/j.molonc.2012.11.003
6. Lin DC, Yin T, Koren-Michowitz M et al (2012) Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3. Blood 120:3310-3317. doi:10.1182/blood-2011-10-388611
7. Kazi JU, Rönnstrand L (2012) Src-Like adaptor protein (SLAP) binds to the receptor tyrosine kinase Flt3 and modulates receptor stability and downstream signaling. PLoS One 7:e53509. doi:10.1371/journal.pone.0053509
8. Lennartsson J, Rönnstrand L (2012) Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev 92:1619-1649. doi:10.1152/physrev.00046.2011
9. Masson K, Rönnstrand L (2009) Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell Signal 21:1717-1726. doi:10.1016/j.cellsig.2009.06.002
10. Yoshimura A, Ohkubo T, Kiguchi T et al (1995) A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 14:2816-2826
11. Masuhara M, Sakamoto H, Matsumoto A et al (1997) Cloning and characterization of novel CIS family genes. Biochem Biophys Res Commun 239:439-446. doi:10.1006/bbrc.1997.7484 (Pubitemid 27488982)
12. Endo TA, Masuhara M, Yokouchi M et al (1997) A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387:921-924. doi:10.1038/43213 (Pubitemid 27289595)
13. Starr R, Willson TA, Viney EM et al (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387:917-921. doi:10.1038/43206 (Pubitemid 27289594)
14. Hilton DJ, Richardson RT, Alexander WS et al (1998) Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA 95:114-119 (Pubitemid 28103916)
15. Kile BT, Alexander WS (2001) The suppressors of cytokine signalling (SOCS). Cell Mol Life Sci 58:1627-1635 (Pubitemid 32996098)
16. Kazi JU, Rönnstrand L (2013) Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling. Mol Oncol 7:693-703. doi:10.1016/j.molonc.2013.02.020
17. Kazi JU, Sun J, Phung B, Zadjali F, Flores-Morales A, Rönnstrand L (2012) Suppressor of cytokine signaling 6 (SOCS6) negatively regulates Flt3 signal transduction through direct binding to phosphorylated tyrosines 591 and 919 of Flt3. J Biol Chem 287:36509-36517. doi:10.1074/jbc.M112.376111
18. Bayle J, Letard S, Frank R, Dubreuil P, De Sepulveda P (2004) Suppressor of cytokine signaling 6 associates with KIT and regulates KIT receptor signaling. J Biol Chem 279:12249-12259. doi:10.1074/jbc.M313381200 (Pubitemid 38445790)
19. Kawazoe Y, Naka T, Fujimoto M et al (2001) Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation. J Exp Med 193:263-269 (Pubitemid 32524458)
20. Jamieson E, Chong MM, Steinberg GR et al (2005) Socs1 deficiency enhances hepatic insulin signaling. J Biol Chem 280:31516-31521. doi:10.1074/jbc. M502163200 (Pubitemid 41291894)
21. Wiejak J, Dunlop J, Gao S, Borland G, Yarwood SJ (2012) Extracellular signal-regulated kinase mitogen-activated protein kinase-dependent SOCS-3 gene induction requires c-Jun, signal transducer and activator of transcription 3, and specificity protein 3 transcription factors. Mol Pharmacol 81:657-668. doi:10.1124/mol.111.076976
22. Iglesias-Gato D, Chuan YC, Wikström P et al (2014) SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer. Carcinogenesis 35:24-33. doi:10.1093/carcin/bgt304
23. Okochi O, Hibi K, Sakai M et al (2003) Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clin Cancer Res 9:5295-5298 (Pubitemid 37413582)
24. He B, You L, Uematsu K et al (2003) SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 100:14133-14138. doi:10.1073/pnas.2232790100 (Pubitemid 37499203)
25. De Sepulveda P, Okkenhaug K, Rose JL, Hawley RG, Dubreuil P, Rottapel R (1999) Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation. EMBO J 18:904-915. doi:10.1093/emboj/18.4.904 (Pubitemid 29082270)
26. Reddy PN, Sargin B, Choudhary C et al (2012) SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control. Blood 120:1691-1702. doi:10.1182/blood- 2010-08-301416
27. Rottapel R, Ilangumaran S, Neale C et al (2002) The tumor suppressor activity of SOCS-1. Oncogene 21:4351-4362. doi:10.1038/sj.onc.1205537 (Pubitemid 34774838)
28. Rui L, Yuan M, Frantz D, Shoelson S, White MF (2002) SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277:42394-42398. doi:10.1074/jbc.C200444200 (Pubitemid 35257562)
29. Ueki K, Kondo T, Kahn CR (2004) Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24:5434-5446. doi:10.1128/MCB.24.12.5434-5446.2004 (Pubitemid 38738176)
30. Bourette RP, De Sepulveda P, Arnaud S, Dubreuil P, Rottapel R, Mouchiroud G (2001) Suppressor of cytokine signaling 1 interacts with the macrophage colony-stimulating factor receptor and negatively regulates its proliferation signal. J Biol Chem 276:22133-22139. doi:10.1074/jbc.M101878200
31. Yu W, Chen J, Xiong Y et al (2008) CSF-1 receptor structure/function in MacCsf1r-/- macrophages: regulation of proliferation, differentiation, and morphology. J Leukoc Biol 84:852-863. doi:10.1189/jlb.0308171
32. Gui Y, Yeganeh M, Ramanathan S et al (2011) SOCS1 controls liver regeneration by regulating HGF signaling in hepatocytes. J Hepatol 55:1300-1308. doi:10.1016/j.jhep.2011.03.027
33. Hafizi S, Alindri F, Karlsson R, Dahlback B (2002) Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 domain-containing protein with homology to tensin. Biochem Biophys Res Commun 299:793-800 (Pubitemid 36034556)
34. Dey BR, Spence SL, Nissley P, Furlanetto RW (1998) Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor. J Biol Chem 273:24095-24101 (Pubitemid 28435753)
35. Xia L, Wang L, Chung AS et al (2002) Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. J Biol Chem 277:30716-30723. doi:10.1074/jbc.M202823200 (Pubitemid 34970768)
36. Ben-Zvi T, Yayon A, Gertler A, Monsonego-Ornan E (2006) Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling. J Cell Sci 119:380-387. doi:10.1242/jcs.02740 (Pubitemid 43210706)
37. Choudhary C, Brandts C, Schwable J et al (2007) Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 110:370-374. doi:10.1182/blood-2006-05-024018 (Pubitemid 47026856)
38. Gui Y, Yeganeh M, Cepero-Donates Y, Ramanathan S, Saucier C, Ilangumaran S (2013) Regulation of MET receptor signaling by SOCS1 and its implications for hepatocellular carcinoma. Curr Pharm Des 19:1-12
39. Kazi JU, Agarwal S, Sun J, Bracco E, Rönnstrand L (2014) Src-like adaptor protein (SLAP) differentially regulates normal and oncogenic c-Kit signaling. J Cell Sci 127:653-662. doi:10.1242/jcs.140590
40. Gulli LF, Palmer KC, Chen YQ, Reddy KB (1996) Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity. Cell Growth Differ 7:173-178 (Pubitemid 26049825)
41. Oveland E, Wergeland L, Hovland R, Lorens JB, Gjertsen BT, Fladmark KE (2012) Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines. Cell Biol Toxicol 28:201-212. doi:10.1007/s10565-012-9216-z
42. Greenhalgh CJ, Rico-Bautista E, Lorentzon M et al (2005) SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest 115:397-406. doi:10.1172/JCI22710 (Pubitemid 40385481)
43. Vesterlund M, Zadjali F, Persson T et al (2011) The SOCS2 ubiquitin ligase complex regulates growth hormone receptor levels. PLoS One 6:e25358. doi:10.1371/journal.pone.0025358
44. Lopaczynski W (1999) Differential regulation of signaling pathways for insulin and insulin-like growth factor I. Acta Biochim Pol 46:51-60
45. Kazi JU, Kabir NN, Rönnstrand L (2013) Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia. Med Oncol 30:575. doi:10.1007/s12032-013-0757-7
46. Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore PP, Dikic I (2003) Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol 5:461-466. doi:10.1038/ncb983 (Pubitemid 36592270)
47. Farabegoli F, Ceccarelli C, Santini D, Taffurelli M (2005) Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma. J Clin Pathol 58:1046-1050. doi:10.1136/jcp.2004.024919 (Pubitemid 41416053)
48. Goldshmit Y, Walters CE, Scott HJ, Greenhalgh CJ, Turnley AM (2004) SOCS2 induces neurite outgrowth by regulation of epidermal growth factor receptor activation. J Biol Chem 279:16349-16355. doi:10.1074/jbc.M312873200 (Pubitemid 38509331)
49. Roberts AW, Robb L, Rakar S et al (2001) Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci USA 98:9324-9329. doi:10.1073/pnas.161271798 (Pubitemid 32743915)
50. Mori H, Hanada R, Hanada T et al (2004) Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med 10:739-743. doi:10.1038/nm1071 (Pubitemid 38937640)
51. Jo D, Liu D, Yao S, Collins RD, Hawiger J (2005) Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat Med 11:892-898. doi:10.1038/nm1269 (Pubitemid 41161123)
52. Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E (2000) SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 275:15985-15991 (Pubitemid 30366903)
53. Emanuelli B, Peraldi P, Filloux C et al (2001) SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 276:47944-47949. doi:10.1074/jbc. M104602200
54. Dey BR, Furlanetto RW, Nissley P (2000) Suppressor of cytokine signaling (SOCS)-3 protein interacts with the insulin-like growth factor-I receptor. Biochem Biophys Res Commun 278:38-43. doi:10.1006/bbrc.2000.3762
55. Zolotnik IA, Figueroa TY, Yaspelkis BB 3rd (2012) Insulin receptor and IRS-1 co-immunoprecipitation with SOCS-3, and IKKalpha/beta phosphorylation are increased in obese Zucker rat skeletal muscle. Life Sci 91:816-822. doi:10.1016/j.lfs.2012.08.038
56. Peraldi P, Filloux C, Emanuelli B, Hilton DJ, Van Obberghen E (2001) Insulin induces suppressor of cytokine signaling-3 tyrosine phosphorylation through janus-activated kinase. J Biol Chem 276:24614-24620. doi:10.1074/jbc.M102209200
57. Sundaram K, Senn J, Reddy SV (2013) SOCS-1/3 participation in FGF-2 signaling to modulate RANK ligand expression in Paget's disease of bone. J Cell Biochem 114:2032-2038. doi:10.1002/jcb.24554
58. Cacalano NA, Sanden D, Johnston JA (2001) Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras. Nat Cell Biol 3:460-465. doi:10.1038/35074525 (Pubitemid 32422081)
59. Kario E, Marmor MD, Adamsky K et al (2005) Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem 280:7038-7048. doi:10.1074/jbc.M408575200 (Pubitemid 40341260)
60. Bullock AN, Rodriguez MC, Debreczeni JE, Songyang Z, Knapp S (2007) Structure of the SOCS4-ElonginB/C complex reveals a distinct SOCS box interface and the molecular basis for SOCS-dependent EGFR degradation. Structure 15:1493-1504. doi:10.1016/j.str.2007.09.016 (Pubitemid 350051927)
61. Nicholson SE, Metcalf D, Sprigg NS et al (2005) Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling. Proc Natl Acad Sci USA 102:2328-2333. doi:10.1073/pnas.0409675102 (Pubitemid 40279375)
62. Linossi EM, Chandrashekaran IR, Kolesnik TB et al (2013) Suppressor of cytokine signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1. PLoS One 8:e70536. doi:10.1371/journal.pone.0070536
63. Lai RH, Hsiao YW, Wang MJ et al (2010) SOCS6, down-regulated in gastric cancer, inhibits cell proliferation and colony formation. Cancer Lett 288:75-85. doi:10.1016/j.canlet.2009.06.025
64. Sriram KB, Larsen JE, Savarimuthu Francis SM et al (2012) Array-comparative genomic hybridization reveals loss of SOCS6 is associated with poor prognosis in primary lung squamous cell carcinoma. PLoS One 7:e30398. doi:10.1371/journal.pone.0030398
65. Krebs DL, Uren RT, Metcalf D et al (2002) SOCS-6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation. Mol Cell Biol 22:4567-4578 (Pubitemid 34620394)
66. Li L, Grønning LM, Anderson PO et al (2004) Insulin induces SOCS-6 expression and its binding to the p85 monomer of phosphoinositide 3-kinase, resulting in improvement in glucose metabolism. J Biol Chem 279:34107-34114. doi:10.1074/jbc.M312672200
67. Mooney RA, Senn J, Cameron S et al (2001) Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 276:25889-25893. doi:10.1074/jbc.M010579200
68. Hwang MN, Ha TH, Park J et al (2007) Increased SOCS6 stability with PMA requires its N-terminal region and the Erk pathway via Pkcdelta activation. Biochem Biophys Res Commun 354:184-189. doi:10.1016/j.bbrc.2006.12.175 (Pubitemid 46151685)
69. Zadjali F, Pike AC, Vesterlund M et al (2011) Structural basis for c-KIT inhibition by the suppressor of cytokine signaling 6 (SOCS6) ubiquitin ligase. J Biol Chem 286:480-490. doi:10.1074/jbc.M110.173526
70. Sitko JC, Guevara CI, Cacalano NA (2004) Tyrosine-phosphorylated SOCS3 interacts with the Nck and Crk-L adapter proteins and regulates Nck activation. J Biol Chem 279:37662-37669. doi:10.1074/jbc.M404007200 (Pubitemid 39195479)
71. Matuoka K, Miki H, Takahashi K, Takenawa T (1997) A novel ligand for an SH3 domain of the adaptor protein Nck bears an SH2 domain and nuclear signaling motifs. Biochem Biophys Res Commun 239:488-492. doi:10.1006/bbrc.1997.7492 (Pubitemid 27488991)
72. Martens N, Wery M, Wang P et al (2004) The suppressor of cytokine signaling (SOCS)-7 interacts with the actin cytoskeleton through vinexin. Exp Cell Res 298:239-248. doi:10.1016/j.yexcr.2004.04.002 (Pubitemid 38887323)
73. Banks AS, Li J, McKeag L et al (2005) Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans. J Clin Invest 115:2462-2471. doi:10.1172/JCI23853 (Pubitemid 41266208)
74. Sasi W, Ye L, Jiang WG, Mokbel K, Sharma A (2013) Observations on the effects of suppressor of cytokine signaling 7 (SOCS7) knockdown in breast cancer cells: their in vitro response to Insulin like growth factor I (IGF-I). Clin Transl Oncol. doi:10.1007/s12094-013-1107-0
75. Krejci P, Prochazkova J, Bryja V et al (2009) Fibroblast growth factor inhibits interferon gamma-STAT1 and interleukin 6-STAT3 signaling in chondrocytes. Cell Signal 21:151-160. doi:10.1016/j.cellsig.2008.10.006
76. Chen S, Anderson PO, Li L, Sjögren HO, Wang P, Li SL (2003) Functional association of cytokine-induced SH2 protein and protein kinase C in activated T cells. Int Immunol 15:403-409 (Pubitemid 36336553)
77. Raccurt M, Tam SP, Lau P et al (2003) Suppressor of cytokine signalling gene expression is elevated in breast carcinoma. Br J Cancer 89:524-532. doi:10.1038/sj.bjc.6601115 (Pubitemid 37026438)
78. Sasi W, Jiang WG, Sharma A, Mokbel K (2010) Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer. BMC Cancer 10:178. doi:10.1186/1471-2407-10-178
79. Li Z, Metze D, Nashan D et al (2004) Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol 123:737-745. doi:10.1111/j.0022-202X.2004.23408.x (Pubitemid 39281615)
80. Zhang J, Li H, Yu JP, Wang SE, Ren XB (2012) Role of SOCS1 in tumor progression and therapeutic application. Int J Cancer 130:1971-1980. doi:10.1002/ijc.27318
81. Mottok A, Renne C, Seifert M et al (2009) Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. Blood 114:4503-4506. doi:10.1182/blood-2009-06-225839
82. Hanada T, Kobayashi T, Chinen T et al (2006) IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med 203:1391-1397. doi:10.1084/jem.20060436 (Pubitemid 43877600)
83. Weniger MA, Melzner I, Menz CK et al (2006) Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 25:2679-2684. doi:10.1038/sj.onc.1209151
84. Hiwatashi K, Tamiya T, Hasegawa E et al (2011) Suppression of SOCS3 in macrophages prevents cancer metastasis by modifying macrophage phase and MCP2/CCL8 induction. Cancer Lett 308:172-180. doi:10.1016/j.canlet.2011.04.024
85. Qiu X, Zheng J, Guo X et al (2013) Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis. Mol Cell Biochem 378:99-106. doi:10.1007/s11010-013-1599-5
86. Zhu JG, Dai QS, Han ZD et al (2013) Expression of SOCSs in human prostate cancer and their association in prognosis. Mol Cell Biochem 381:51-59. doi:10.1007/s11010-013-1687-6
87. Iglesias-Gato D, Chuan YC, Wikström P et al (2013) SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer. Carcinogenesis. doi:10.1093/carcin/bgt304
88. Niwa Y, Kanda H, Shikauchi Y et al (2005) Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 24:6406-6417. doi:10.1038/sj.onc. 1208788 (Pubitemid 41486474)
89. Zhang L, Li J, Li L et al (2014) IL-23 selectively promotes the metastasis of colorectal carcinoma cells with impaired Socs3 expression via the STAT5 pathway. Carcinogenesis. doi:10.1093/carcin/bgu017
90. Sakai I, Takeuchi K, Yamauchi H, Narumi H, Fujita S (2002) Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood 100:2926-2931. doi:10.1182/blood-2002-01-0073
91. Suessmuth Y, Elliott J, Percy MJ et al (2009) A new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses. Br J Haematol 147:450-458. doi:10.1111/j.1365-2141.2009.07860.x
92. Quentmeier H, Geffers R, Jost E et al (2008) SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia 22:2169-2175. doi:10.1038/leu.2008.226
93. Jost E, ON do, Dahl E et al (2007) Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia 21:505-510. doi:10.1038/sj.leu.2404513
94. Etienne A, Carbuccia N, Adelaide J et al (2007) Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes. Cancer Genet Cytogenet 176:80-88. doi:10.1016/j.cancergencyto.2007.03.009 (Pubitemid 46899216)
95. Fourouclas N, Li J, Gilby DC et al (2008) Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica 93:1635-1644. doi:10.3324/haematol.13043
96. Haan S, Ferguson P, Sommer U et al (2003) Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation. J Biol Chem 278:31972-31979. doi:10.1074/jbc.M303170200 (Pubitemid 37048385)
97. Ueki K, Kondo T, Tseng YH, Kahn CR (2004) Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci USA 101:10422-10427. doi:10.1073/pnas.0402511101 (Pubitemid 38924941)
98. Ueki K, Kadowaki T, Kahn CR (2005) Role of suppressors of cytokine signaling SOCS-1 and SOCS-3 in hepatic steatosis and the metabolic syndrome. Hepatol Res 33:185-192. doi:10.1016/j.hepres.2005.09.032 (Pubitemid 41799802)
99. Kato H, Nomura K, Osabe D et al (2006) Association of single-nucleotide polymorphisms in the suppressor of cytokine signaling 2 (SOCS2) gene with type 2 diabetes in the Japanese. Genomics 87:446-458. doi:10.1016/j.ygeno.2005.11.009
100. Ramos MI, Perez SG, Aarrass S et al (2013) FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis in rheumatoid arthritis. Arthritis Res Ther 15:R209. doi:10.1186/ar4403
101. Madan B, Goh KC, Hart S et al (2012) SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritis. J Immunol 189:4123-4134. doi:10.4049/jimmunol.1200675
102. Juurikivi A, Sandler C, Lindstedt KA et al (2005) Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann Rheum Dis 64:1126-1131. doi:10.1136/ard.2004.029835 (Pubitemid 41113344)
103. Tsao JT, Kuo CC, Lin SC (2008) The analysis of CIS, SOCS1, SOSC2 and SOCS3 transcript levels in peripheral blood mononuclear cells of systemic lupus erythematosus and rheumatoid arthritis patients. Clin Exp Med 8:179-185. doi:10.1007/s10238-008-0006-0
104. Chen YH, Hsieh SC, Chen WY et al (2011) Spontaneous resolution of acute gouty arthritis is associated with rapid induction of the anti-inflammatory factors TGFbeta1, IL-10 and soluble TNF receptors and the intracellular cytokine negative regulators CIS and SOCS3. Ann Rheum Dis 70:1655-1663. doi:10.1136/ard.2010.145821
105. De Souza D, Fabri LJ, Nash A, Hilton DJ, Nicola NA, Baca M (2002) SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities. Biochemistry 41:9229-9236 (Pubitemid 34787281)
106. Puissant A, Fenouille N, Alexe G et al (2014) SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell 25:226-242. doi:10.1016/j.ccr. 2014.01.022
107. Kabir NN, Kazi JU (2014) Grb10 is a dual regulator of receptor tyrosine kinase signaling. Mol Biol Rep. doi:10.1007/s11033-014-3046-4
108. Neuwirt H, Puhr M, Santer FR et al (2009) Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through downregulation of cyclins and cyclin-dependent kinases. Am J Pathol 174:1921-1930. doi:10.2353/ajpath.2009. 080751